RecruitingNot applicableNCT05776472
A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Studying Paroxysmal nocturnal hemoglobinuria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Swedish Orphan Biovitrum
- Principal Investigator
- Study Physician +46 08-697-20 00, medical.info@sobi.comSwedish Orphan Biovitrum
- Intervention
- Pegcetacoplan(drug)
- Enrollment
- 200 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (20)
- Liverpool Hospital, Liverpool, New South Wales, Australia
- Calvary Mater Newcastle, Waratah, New South Wales, Australia
- Sunshine Coast University Hospital, Birtinya, Queensland, Australia
- AZ Sint-Jan, Bruges, Belgium
- CHU Brugmann-Site Horta, Brussels, Belgium
- Centre Hospitalier Universitaire de Liege, Liège, Belgium
- AZ Turnhout - Campus Sint-Elisabeth, Turnhout, Belgium
- University Health Network, Toronto, Ontario, Canada
- Hopital Maisonneuve-Rosemont d/b/a CIUSSS de l'Est-de-l'Île-de-Montréal, Montreal, Quebec, Canada
- Fakultni nemocnice Brno, Brno, Czechia
- Ustav hematologie a krevni transfuze, Prague, Czechia
- Helsingin yliopistollinen keskussairaala, Helsinki, Finland
- CHU Nice - Hôpital de l'Archet 1, Nice, Alpes Maritimes, France
- CHU de Bordeaux - Hôpital Haut-Lévêque, Pessac, Gironde, France
- Hopital Foch, Suresnes, Hauts De Seine, France
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05776472 on ClinicalTrials.govOther trials for Paroxysmal nocturnal hemoglobinuria
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07457151Danicopan PMS in KoreaAstraZeneca
- RECRUITINGPHASE3NCT07154745A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working EfficientlyRegeneron Pharmaceuticals
- RECRUITINGPHASE1NCT07462780A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy ParticipantsShenzhen Kangzhe Biotechnology Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07470762Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal HemoglobinuriaJiangsu Hansoh Pharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07187401A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 InhibitorRegeneron Pharmaceuticals
- ACTIVE NOT RECRUITINGNCT07413250Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry DataAlexion Pharmaceuticals, Inc.
- RECRUITINGNCT07229235REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal HemoglobinuriaNovartis Pharmaceuticals
- RECRUITINGPHASE3NCT06934967Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH PatientsNovartis Pharmaceuticals